Invion Limited Stock price

Equities

IVX

AU000000IVX4

Biotechnology & Medical Research

Market Closed - Australian S.E. 01:10:10 2024-03-28 am EDT 5-day change 1st Jan Change
0.006 AUD +20.00% Intraday chart for Invion Limited +20.00% +20.00%
Sales 2022 3.29M 2.14M Sales 2023 4.1M 2.67M Capitalization 25.69M 16.71M
Net income 2022 -2M -1.3M Net income 2023 -1M -651K EV / Sales 2022 15 x
Net cash position 2022 8.47M 5.51M Net cash position 2023 4.08M 2.66M EV / Sales 2023 5.26 x
P/E ratio 2022
-22.6 x
P/E ratio 2023
-13.4 x
Employees 4
Yield 2022 *
-
Yield 2023
-
Free-Float 50.95%
More Fundamentals * Assessed data
Dynamic Chart
1 day+20.00%
1 week+20.00%
Current month+20.00%
1 month+20.00%
6 months+20.00%
Current year+20.00%
More quotes
1 week
0.01
Extreme 0.005
0.01
1 month
0.00
Extreme 0.004
0.01
Current year
0.00
Extreme 0.004
0.01
1 year
0.00
Extreme 0.004
0.01
3 years
0.00
Extreme 0.004
0.03
5 years
0.00
Extreme 0.004
0.03
10 years
0.00
Extreme 0.002
0.09
More quotes
Managers TitleAgeSince
Chief Executive Officer - 17-11-30
Director of Finance/CFO 51 20-07-12
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member - 20-10-21
Chief Executive Officer - 17-11-30
Director/Board Member 74 19-02-11
More insiders
Date Price Change Volume
24-03-28 0.006 +20.00% 5,474,813
24-03-27 0.005 0.00% 50,000
24-03-26 0.005 -9.09% 2,263
24-03-25 0.0055 +10.00% 254,994
24-03-21 0.005 0.00% 125,173

Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT

More quotes
Invion Limited is an Australia-based life sciences company. The Company is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The Company is engaged in the clinical development of a PhotoDynamic Therapy (PDT) for cancer. Its photosensitizer (the agent used in PDT) is called IVX-PDT and is based on Photosoft Technology. Its PDT is an alternative to surgery, and in contrast to radiotherapy and chemotherapy, which are immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumor by leukocytes. It produces topical and intravenous products suitable for use in skin cancer and in solid tumors, such as those present in ovarian, prostate and lung cancer. It is developing a topical formulation of its photosensitizing agent, IVX-PDT, to treat superficial Basal Cell Carcinoma (sBCC), Actinic Keratosis (AK) and Squamous Cell Cancer (SCC).
More about the company
  1. Stock
  2. Equities
  3. Stock Invion Limited - Australian S.E.